Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02221960 | A Phase 1 Study to Evaluate MEDI6383 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors | PHASE1 | COMPLETED | 39 | — | — | Sep 15, 2014 | Jul 3, 2017 | Mar 13, 2019 | 8 | United States, Australia |
Primary endpoint will be the number (%) of subjects with adverse events and serious adverse events.
| Arm | Type | Description |
|---|---|---|
| Monotherapy Arm | EXPERIMENTAL | MEDI6383 |
| Combination Arm | EXPERIMENTAL | MEDI6383 and MEDI4736 |
| Name | Type | Description |
|---|---|---|
| MEDI6383 | BIOLOGICAL | Subjects will receive MEDI6383 until disease progression or adverse event. |
| MEDI6383 and MEDI4736 | BIOLOGICAL | Subjects will recieve MEDI6383 and MEDI4736 until disease progression or adverse event. |
Inclusion Criteria: 1. Male and female subjects; age ≥ 18 2. Written informed consent must be obtained 3. Subjects must meet the following criteria: 1. Have recurrent or metastatic solid tumors 2. Must have received and have progressed, are refractory, or are intolerant to standard therapy a...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab, V503, GARDASIL |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| AstraZeneca PLC | AZN | 1 | — | Trastuzumab deruxtecan |